Aventis Merger Would Bring New Blood To Novartis’ Cardiology R&D
Executive Summary
A merger with Aventis would invigorate Novartis' cardiology portfolio with the addition of an early-stage cardiovascular pipeline
You may also be interested in...
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011